Convergen Secures $10 Million Seed Funding to Advance TrimTAC Platform for Neurodegeneration beyond
- Written by PR Newswire
![]() |
SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Convergen, a biotech company pioneering targeted protein degradation (TPD) therapies for diseases driven by pathological protein aggregates, today announced the closing of a $10 million Seed financing round. The round was invested by Qiming Venture Partners, a leading global venture capital firm focused...















